Sorrento Therapeutics Officers, Directors Targeted in Trustee’s Adversary Proceeding
The liquidating trustee overseeing the Sorrento Therapeutics Chapter 11 bankruptcy filed an adversary proceeding this week against the company’s directors and officers, alleging their breaches of fiduciary duty caused the company’s creditors to suffer at least $100 million in damages.